PBAC's latest decision on Tiotropium bromide with olodaterol hydrochloride: Recommended with restriction (2017). Considered for Chronic obstructive pulmonary disease (COPD) in patients with persistent symptoms despite regular monotherapy with a long-acting muscarinic antagonist (LAMA) or long-acting beta-2 agonist (LABA), or in patients stabilised on combination LAMA and LABA therapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Adults with COPD who have persistent symptoms despite regular bronchodilator treatment with a LAMA or LABA monotherapy, or who are stabilised on concomitant LAMA and LABA therapy.
Therapy area
Respiratory
Line of therapy
Second-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
other LAMA/LABA fixed-dose combinations (umeclidinium with vilanterol, aclidinium with eformoterol, indacaterol with glycopyrronium)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Minor submission with budget impact analysis showing net saving.